Table 4.
mCRPC drug usage by 4 index year–based cohort
| Commercial Claims Database | ||||||
|---|---|---|---|---|---|---|
| Number of patients using an mCRPC drug regimena | Number of chemotherapyb vsnonchemotherapyc mCRPC drug regimensd | |||||
| Cohort | LOT1 | LOT2+ | LOT1 chemotherapy | LOT1 Nonchemotherapy agent | LOT2+ chemotherapy | LOT2+ nonchemotherapy agent |
| 2000–2003 | 175 | 66 | 166 | 0 | 65 | 0 |
| 2004–2008 | 1124 | 362 | 1077 | 0 | 314 | 33 |
| 2009–2013 | 2138 | 789 | 1149 | 918 | 344 | 586 |
LOT1, first line of therapy; LOT2+, beyond second line of therapy; mCRPC, metastatic castration‐resistant prostate cancer.
a
Excludes patients who used carboplatin.
b
Cabazitaxel, docetaxel, estramustine, mitoxantrone.
c
Abiraterone acetate, enzalutamide, sipuleucel‐T.
d
Differences in utilization pattern of chemotherapy and nonchemotherapy mCRPC drug regimens were significant in LOT1 (P < 0.0001) and LOT2+ (P < 0.0001).